DAFTAR PUSTAKA


ALLHAT. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) (2002). *JAMA* 288, 2981–2997


Bray GA (1998). In defense of a body mass index of 25as the cut-off point for defining overweight. ObesRes 6, 461-462


Bray GA. Medical Consequences of Obesity (2004). J Clin Endocrinol Metab89, 2583–2589


Desilets AR, Dhakal-Karki S, and Duncan KC (2008). Role of Metformin for Weight Management in Patients Without Type 2 Diabetes. *Ann Pharmacother* 42, 817-826


Freemark M, Bursey D (2001). The Effects of Metformin on Body Mass Index and Glucose Tolerance in Obese Adolescents With Fasting Hyperinsulinemia and a Family History of Type 2 Diabetes. *Pediatrics* 107, 1-7


Hainer V, Toplak H, Mitrakou A (2008); Treatment Modalities of Obesity What fits whom?. *Diabetes Care* 31 (Suppl. 2), S269–S277


Circulation 104, 2673-2678


J Clin Endocrinol Metab 88, 3554-3560


J.Clin. Invest 91, 1358-1366

Hong Y, Pedersen NL, Brismar K, de Faire U (1997). Genetic and environmental architecture of the features of the insulin-resistance syndrome. 

Am J Hum Genet 60, 143-152


JAMA 295, 39-49


N Engl J Med 337, 1491–1499


Arch Intern Med. 164, 1066 –1076


Am J Clin Nutr 76, 473–481


J Formos Med Assoc 105, 626–635


Diabetes Care 31, 805–807


Cell 115, 577–590


Johnson AG, Nguyen TV, Daviseralal D (2001). Blood pressure is linked to salt intake and modulated by the angiotensinogen gene in normotensive and hypertensive elderly subjects. J Hypertens 19,1053–1060


Lee J, Ma S, Heng D (2007). Should central obesity be an optional or essential component of the metabolic syndrome? Ischemic heart disease risk in the Singapore Cardiovascular Cohort Study. Diabetes Care 30, 343-347


Lewis GF, Steiner G (1996). Acute effects of insulin in the control of VLDL production in humans. Implications for the insulin-resistant state. Diabetes Care 19, 390–393


Moran R, Romero GF, (2003). Elevated concentrations of C-reactive protein in subjects with type 2 diabetes mellitus are moderately influenced by glycemic control. *J Endocrinol Invest.* 26, 216-221


Nichols GA (2007), Gomez-Caminero A. Weight changes following the initiation of new anti-hyperglycaemic therapies. *Diabetes Obes Metab* 9, 96-102


Universitas Sumatera Utara


Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J (2006). Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 295, 761-775


Riset Kesehatan Dasar (RISKESDAS) Nasional 2007


Rotter V, Nagaev I, Smith U (2003). Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overweight expressed in human fat cells from insulin-resistant subjects. J Biol Chem 278, 45777–45784


Schindler C (2007). The metabolic syndrome as an endocrine disease: is there an effective pharmacotherapeutic strategy optimally targeting the pathogenesis? *Ther Adv Cardiovasc Dis* 1, 7–26


Scirica BM, Morrow DA (2006). Is C-reactive protein an innocent bystander or proatherogenic culprit? The verdict is still out. *Circulation* 113, 2128–2134


Tjokroprawiro A. A Memorial review Article for the-Year Clinical Experiences with Metformin (It is more Than Oral Anti Diabetes Agent). Naskah Lengkap Surabaya Metabolic Syndrome Update-5 (Sumetsu-5) (2009), Metabolic Cardiovascular Disease Surabaya Update-4 (Mecarsu-4). Editor oleh Tjokroprawiro A, Sutjahjo Ari, Pronoto A dkk. Surabaya 8-10 Mei, 238-255


Tjokroprawiro A. Metabolic- syndrome: Capita selecta (From Basic to Possible Clinical Application) (2008). Naskah lengkap Surabaya Metabolic Syndrome (Sumetsu-4), Metabolic Cardiovascular Disease Surabaya (Mecarsu-2). Editor oleh Tjokroprawiro A, Sutjahjo Ari, Pronoto A dkk. Surabaya, 79-89


